文献速递慢性肾脏病血液净化与透析

2型糖尿病中度心血管风险患者中GLP-1RA、SGLT2i、DPP-4i与磺脲类的肾脏结局比较

Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-10-08

该回顾性观察性研究模拟目标试验,利用OptumLabs理赔数据比较2型糖尿病伴中度心血管风险患者起始DPP-4i、SGLT2i、GLP-1RA或磺脲类对肾脏复合结局的影响。共纳入364,714例成人,结果显示SGLT2i和GLP-1RA在预防肾脏并发症方面优于DPP-4i和磺脲类,且SGLT2i在肾脏结局上优于GLP-1RA。

要点

  • SGLT2i和GLP-1RA预防肾脏并发症优于DPP-4i和磺脲类。
  • SGLT2i在肾脏复合结局上优于GLP-1RA。
  • 中度心血管风险2型糖尿病患者早期启用SGLT2i或GLP-1RA可能获益。

核心结论

  • 在2型糖尿病伴中度基线心血管风险人群中,SGLT2i和GLP-1RA在预防肾脏并发症方面优于DPP-4i和磺脲类。
  • SGLT2i在肾脏复合结局上优于GLP-1RA。

研究设计与样本

  • 回顾性观察性研究,模拟理想目标试验,使用OptumLabs理赔数据。
  • 纳入364,714例21岁及以上成人,起始DPP-4i(N=78,843)、GLP-1RA(N=42,049)、SGLT2i(N=45,466)或磺脲类(N=198,356)。
  • 主要肾脏复合结局为 incident CKD 3-5期、肾衰竭或需要KRT;次要复合结局包括主要结局所有组分加死亡。

主要发现

  • 相对DPP-4i,SGLT2i主要复合结局HR 0.71(95%CI 0.67-0.74,P<0.001),GLP-1RA HR 0.87(95%CI 0.83-0.92,P<0.001)。
  • 相对磺脲类,SGLT2i主要结局HR 0.69(95%CI 0.66-0.73),GLP-1RA HR 0.86(95%CI 0.82-0.91)。
  • SGLT2i对比GLP-1RA主要复合结局HR 0.81(95%CI 0.75-0.86,P<0.001),SGLT2i更优。
  • 次要复合结局在所有比较中观察到相似结果。

临床怎么用

  • 对于2型糖尿病伴中度心血管风险患者,可考虑优先选用SGLT2i或GLP-1RA以降低肾脏并发症风险。
  • 在肾脏结局方面,SGLT2i可能较GLP-1RA更具优势。

局限性

  • 回顾性观察性研究,可能存在残余混杂。
  • 使用理赔数据,结局 ascertainment 可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists were superior to dipeptidyl peptidase-4 inhibitor and sulfonylurea for preventing kidney complications in patients with type 2 diabetes at moderate cardiovascular disease risk. Sodium-glucose cotransporter 2 inhibitor therapy compared favorably with glucagon-like peptide-1 receptor agonists for kidney disease outcomes. BACKGROUND: CKD is a serious diabetes-related complication. While guidelines recommend use of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapies to mitigate cardiorenal risk in high-risk patients, the benefit of early initiation of these agents relative to other commonly prescribed glucose-lowering agents in patients at lower baseline cardiovascular disease (CVD) risk remains less clear. METHODS: This retrospective observational study emulated an idealized target trial using claims data from OptumLabs data warehouse to test the comparative association of treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4i), SGLT2i, GLP-1RA, or sulfonylurea (SU) on a primary kidney composite outcome of incident CKD stages 3-5, kidney failure, or need for KRT in patients with type 2 diabetes and moderate CVD risk. A secondary composite outcome included all components of the primary composite outcome plus death. RESULTS: A total of 364,714 adults aged 21 years or older initiating treatment with a DPP-4i ( N =78,843), GLP-1RA ( N =42,049), SGLT2i ( N =45,466), or SU ( N =198,356) were identified. Relative to DPP-4i, SGLT2i (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.67 to 0.74; P < 0.001) and GLP-1RA (HR, 0.87; 95% CI, 0.83 to 0.92; P < 0.001) treatment was superior for the primary composite outcome. Similarly, SGLT2i (HR, 0.69; 95% CI, 0.66 to 0.73) and GLP-1RA (HR, 0.86; 95% CI, 0.82 to 0.91) treatment was associated with risk reductions for the primary outcome relative to SU treatment. When comparing SGLT2i with GLP-1RA therapy, SGLT2is were superior for the primary composite outcome (HR, 0.81; 95% CI, 0.75 to 0.86; P < 0.001). Similar findings were observed for the secondary composite outcome across all comparisons. CONCLUSIONS: SGLT2is and GLP-1RAs were superior to DPP-4is and SUs for preventing kidney complications in a type 2 diabetes population with moderate baseline CVD risk. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT05214573 .

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Neumiller JJ, Herrin J, Swarna KS, et al. Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clin J Am Soc Nephrol. 2024. PMID: 39729347. doi:10.2215/CJN.0000000587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。